These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 34452397)
1. Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection. Heuschkel MJ; Baumert TF; Verrier ER Viruses; 2021 Aug; 13(8):. PubMed ID: 34452397 [TBL] [Abstract][Full Text] [Related]
2. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325 [TBL] [Abstract][Full Text] [Related]
3. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP). Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143 [TBL] [Abstract][Full Text] [Related]
6. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Yan H; Li W Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274 [TBL] [Abstract][Full Text] [Related]
7. Strategies to inhibit entry of HBV and HDV into hepatocytes. Urban S; Bartenschlager R; Kubitz R; Zoulim F Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844 [TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. Yan H; Peng B; He W; Zhong G; Qi Y; Ren B; Gao Z; Jing Z; Song M; Xu G; Sui J; Li W J Virol; 2013 Jul; 87(14):7977-91. PubMed ID: 23678176 [TBL] [Abstract][Full Text] [Related]
9. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. Li W; Urban S J Hepatol; 2016 Apr; 64(1 Suppl):S32-S40. PubMed ID: 27084034 [TBL] [Abstract][Full Text] [Related]
10. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Sureau C Methods Mol Biol; 2010; 640():463-73. PubMed ID: 20645068 [TBL] [Abstract][Full Text] [Related]
11. NTCP opens the door for hepatitis B virus infection. Yan H; Liu Y; Sui J; Li W Antiviral Res; 2015 Sep; 121():24-30. PubMed ID: 26071008 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872 [TBL] [Abstract][Full Text] [Related]
13. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168 [TBL] [Abstract][Full Text] [Related]
14. In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Giersch K; Dandri M Viruses; 2021 Mar; 13(4):. PubMed ID: 33807170 [TBL] [Abstract][Full Text] [Related]
15. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Yan H; Zhong G; Xu G; He W; Jing Z; Gao Z; Huang Y; Qi Y; Peng B; Wang H; Fu L; Song M; Chen P; Gao W; Ren B; Sun Y; Cai T; Feng X; Sui J; Li W Elife; 2012 Nov; 3():. PubMed ID: 25409679 [TBL] [Abstract][Full Text] [Related]
16. Interactions of Na Zakrzewicz D; Geyer J Biol Chem; 2023 Jun; 404(7):673-690. PubMed ID: 37103224 [TBL] [Abstract][Full Text] [Related]
17. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446 [TBL] [Abstract][Full Text] [Related]
18. Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo. He W; Cao Z; Mao F; Ren B; Li Y; Li D; Li H; Peng B; Yan H; Qi Y; Sun Y; Wang F; Sui J; Li W J Virol; 2016 Oct; 90(19):8866-74. PubMed ID: 27466423 [TBL] [Abstract][Full Text] [Related]
19. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322 [TBL] [Abstract][Full Text] [Related]
20. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry. Fu L; Hu H; Liu Y; Jing Z; Li W Virology; 2017 May; 505():1-11. PubMed ID: 28213271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]